Lu Kang Medicine: Gefitinib Tablets Obtained Drug Registration Certificate

Lu Kang Pharmaceutical announcement, recently received the "Drug Registration Certificate" for Gefitinib Tablets and the "Chemical Raw Materials Market Application Approval Notice" for Gefitinib APIs issued by the National Medical Products Administration. Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor, suitable for the treatment of locally advanced or metastatic non-small cell lung cancer patients with epidermal growth factor receptor gene-sensitive mutations. There are currently 15 Gefitinib tablet numbers in China, with sales of 263 million yuan in 2024. The company's R&D investment in Gefitinib tablets is approximately 11.1491 million yuan, and the investment in raw materials research and development is approximately 9.9 million yuan.